Get the Stockscreener App
25.38
13.76%
3.07
Lyell Immunopharma Inc stock is traded at $25.38, with a volume of 84,741.
It is up +13.76% in the last 24 hours and up +59.12% over the past month.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
See More
Previous Close:
$22.31
Open:
$22.48
24h Volume:
84,741
Relative Volume:
1.92
Market Cap:
$538.52M
Revenue:
$54,000
Net Income/Loss:
$-210.26M
P/E Ratio:
-32.13
EPS:
-0.79
Net Cash Flow:
$-159.01M
1W Performance:
+3.97%
1M Performance:
+59.12%
6M Performance:
+88.42%
1Y Performance:
+34.70%
1-Day Range:
$21.39
$25.59
1-Week Range:
$20.59
$25.59
52-Week Range:
$7.65
$25.59
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
25.38 | 473.38M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-30-24 | Downgrade | BofA Securities | Buy → Underperform |
| Jun-27-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
Will Lyell Immunopharma Inc. stock sustain high P E ratiosTrade Signal Summary & Growth Oriented Trading Recommendations - Newser
Decheng Capital LLC Sells 11,313,875 Shares of Lyell Immunopharma, Inc. $LYEL - MarketBeat
ASH 2025 Roundup: Companies With Key Data Presentations - RTTNews
What analysts say about Lyell Immunopharma Inc stockInsider Trading Compliance & Individual Stock Tracking Service - earlytimes.in
What drives Lyell Immunopharma Inc stock priceHigh Beta Stocks & Free High Yield Growth Strategies - earlytimes.in
Lyell Immunopharma (NASDAQ:LYEL) Hits New 52-Week HighHere's What Happened - MarketBeat
Published on: 2025-11-26 22:33:12 - BỘ NỘI VỤ
Lyell Immunopharma (LYEL) Sees Price Target Doubling by HC Wainw - GuruFocus
ETFs Investing in Lyell Immunopharma, Inc. Stocks - TradingView
Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) one-year returns climbed after last week's 13% gain, institutional investors must be happy - simplywall.st
Is Lyell Immunopharma Inc. stock trading at a premium valuationJuly 2025 Trends & AI Powered Trade Plan Recommendations - newser.com
How Lyell Immunopharma Inc. stock performs in rate cut cyclesJuly 2025 Momentum & Technical Pattern Based Signals - newser.com
Will Lyell Immunopharma Inc. stock pay special dividendsJuly 2025 Institutional & Accurate Technical Buy Alerts - newser.com
Real time social sentiment graph for Lyell Immunopharma Inc.Weekly Profit Report & Reliable Volume Spike Trade Alerts - newser.com
Will Lyell Immunopharma Inc. benefit from macro trendsQuarterly Portfolio Review & Fast Exit and Entry Trade Guides - newser.com
How Lyell Immunopharma Inc. stock performs in weak economyTrade Exit Summary & Real-Time Stock Entry Alerts - newser.com
Is it too late to sell Lyell Immunopharma Inc.Weekly Investment Recap & Daily Stock Momentum Reports - newser.com
Is Lyell Immunopharma Inc. stock attractive for retirement portfoliosLayoff News & Safe Entry Point Alerts - newser.com
Lyell Immunopharma Secures Global Rights to CAR T-Cell Candidate for Metastatic Colorectal Cancer - Global Legal Chronicle
Strategies to average down on Lyell Immunopharma Inc.July 2025 Institutional & Smart Investment Allocation Tips - newser.com
Published on: 2025-11-16 00:33:42 - newser.com
Is Lyell Immunopharma Inc. still worth holding after the dipSwing Trade & Reliable Volume Spike Trade Alerts - newser.com
Lyell Immunopharma acquires exclusive global rights to LYL273 - MSN
Lyell Immunopharma CSO sells $2230 in shares By Investing.com - Investing.com Nigeria
Lyell Immunopharma COO Hill sells $1.5k in shares By Investing.com - Investing.com Australia
Technical signs of recovery in Lyell Immunopharma Inc.Earnings Beat & Weekly High Conviction Trade Ideas - newser.com
Lyell Immunopharma reports Q3 revenue $15k vs $34k last year - MSN
LYEL SEC FilingsLyell Immunopharma, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Lyell Immunopharma CEO Seely sells $6637 in stock By Investing.com - Investing.com Australia
Lyell Immunopharma: Q3 Earnings Snapshot - CT Insider
Lyell Immunopharma VP sells $3847 in stock By Investing.com - Investing.com Nigeria
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):